- AimedBio has entered into a collaboration and license agreement with Boehringer Ingelheim for a novel antibody-drug conjugate (ADC) therapy for a borad range of cancers.
- Through this agreement, Boehringer Ingelheim has secured the global rights for the development and commercializations of
ADC assets developed by AimedBio, which are based on novel tumor-specific targets selectively expressed in various solid
tumors, including KRAS mutations.
- The candidate incorporates a Topo1 inhibitor payload, offering potent anti-cancer efficacy and high tumor selectivity.
- The goal is to initiate a Phase 1 (First-in-Human) clinical trial in 2026.
Link to full article: https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/new-partnership-helps-advance-our-cancer-adcs-portfolio